AVRO AVROBIO Inc.

17.6
+0.28  (+2%)
Previous Close 17.32
Open 17.18
Price To Book 2.47
Market Cap 634,224,078
Shares 36,035,459
Volume 343,369
Short Ratio
Av. Daily Volume 335,019
Stock charts supplied by TradingView

NewsSee all news

  1. AVROBIO Presents New Preclinical Data on Lentiviral Gene Therapy Program for Pompe Disease at ASGCT 2020

    AVROBIO's optimized lentiviral vectors demonstrate significant glycogen reduction in the muscle and central nervous system of Pompe disease mouse model Investigational New Drug (IND)-enabling proof-of-concept study

  2. AVROBIO Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and Cystinosis

    Sustained enzyme activity up to 22 months and consistent trends demonstrated across multiple other measures in first patient in Fabry disease Phase 2 clinical trial Data from first patient treated using platoTM gene

  3. AVROBIO Reports 1Q 2020 Financial Results and Provides Business Update

    Three oral presentations accepted on new clinical and preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 23rd annual meeting Completed two collaboration agreements to reinforce technological

  4. AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for

  5. AVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies

    Collaboration focuses on advancing innovation with antibody-drug conjugate (ADC)-based conditioning for lentiviral gene therapies Under the collaboration, AVROBIO and Magenta will jointly evaluate MGTA-117 in

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 updated data presented at American Society of Gene & Cell Therapy (ASGCT) May 13, 2020.
AVR-RD-04 (ASGCT)
Cystinosis
Phase 1/2 trial initial data due 2020.
AVR-RD-02
Gaucher disease
Phase 2 trial ongoing.
AVR-RD-01 (FAB-201)
Fabry disease

Latest News

  1. AVROBIO Presents New Preclinical Data on Lentiviral Gene Therapy Program for Pompe Disease at ASGCT 2020

    AVROBIO's optimized lentiviral vectors demonstrate significant glycogen reduction in the muscle and central nervous system of Pompe disease mouse model Investigational New Drug (IND)-enabling proof-of-concept study

  2. AVROBIO Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and Cystinosis

    Sustained enzyme activity up to 22 months and consistent trends demonstrated across multiple other measures in first patient in Fabry disease Phase 2 clinical trial Data from first patient treated using platoTM gene

  3. AVROBIO Reports 1Q 2020 Financial Results and Provides Business Update

    Three oral presentations accepted on new clinical and preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 23rd annual meeting Completed two collaboration agreements to reinforce technological

  4. AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for

  5. AVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies

    Collaboration focuses on advancing innovation with antibody-drug conjugate (ADC)-based conditioning for lentiviral gene therapies Under the collaboration, AVROBIO and Magenta will jointly evaluate MGTA-117 in

  6. Magenta Therapeutics and AVROBIO Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies

    Collaboration focuses on advancing innovation with antibody-drug conjugate (ADC)-based conditioning for lentiviral gene therapies Under the collaboration, Magenta and AVROBIO will jointly evaluate MGTA-117 in

  7. AVROBIO to Present New Clinical and Preclinical Data at Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 12-15, 2020

    Updated data will be presented on first patient dosed in Phase 1/2 clinical trial for cystinosis and first patient treated using plato™ gene therapy platform in Phase 2 Fabry disease clinical trial Company will

  8. AVROBIO to Collaborate with Saladax Biomedical on New High-Speed Diagnostic Assay Used with Busulfan Conditioning to Enable Widespread Commercialization of AVROBIO's Proprietary Platform Globally

    Fully automated immunoassay kit designed to simplify and streamline busulfan therapeutic drug monitoring (TDM), potentially reducing turnaround time from hours to minutes and greatly expanding hospital, clinic, medical

  9. AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for

  10. AVROBIO Outlines Response to COVID-19 and Current Assessment of Business Impact

    Patient identification for clinical trials continues; dosing temporarily paused as clinical trial sites focus on COVID-19 pandemic Essential laboratory and manufacturing activities currently uninterrupted Cash

  11. AVROBIO to Participate in Upcoming April Investor Conferences

    AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team will participate at

  12. AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for

  13. AVROBIO Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update

    Presented positive data at the 16th Annual WORLDSymposium™ on AVR-RD-04 for cystinosis and AVR-RD-01 for Fabry disease, as well as early data on plato™-produced drug product and plasma enzyme activity level Received

  14. AVROBIO Receives Orphan Drug Designation from U.S. FDA for AVR‑RD‑04 for Cystinosis

    AVR-RD-04 is the third AVROBIO investigational gene therapy to receive orphan status AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic

  15. AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for

  16. AVROBIO to Present at the Cowen and Company 40th Annual Health Care Conference

    AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present at

  17. AVROBIO Announces Closing of Underwritten Public Offering

    AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 4,350,000 shares of its common stock. The aggregate

  18. AVROBIO Announces Pricing of Underwritten Public Offering of $100 Million of Common Stock

    AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 4,350,000 shares of its common stock at a public offering price of $23.00 per

  19. AVROBIO Announces Proposed Public Offering of Common Stock

    AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced that it intends to offer and sell, subject to market and other conditions, $100 million of its common stock in an underwritten

  20. AVROBIO Presents Positive Initial Data for its Investigational Cystinosis Program and Plato TM Platform, as well as Positive Data Out to 32 Months for its Ongoing Investigational Fabry Program

    Early data trends from first patient dosed in the AVR-RD-04 investigational gene therapy program for cystinosis show improvements across multiple measures Data from the Phase 1 and Phase 2 trials of AVR-RD-01 support

  21. AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for

  22. AVROBIO Announces Clinical Data Presentation and Multiple Events at WORLDSymposium™ 2020

    Analyst and investor event to be webcast on Monday, Feb. 10, 2020, at 7:00 p.m. ET AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic

  23. AVROBIO Announces Clinical and Regulatory Progress for Gaucher Disease Program

    FDA clears IND application for AVR-RD-02 First patient consented in GAU-201, a global Phase 1/2 trial of AVR-RD-02 in Gaucher disease type 1 All global clinical sites will be supported by proprietary plato™

  24. AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    AVROBIO (NASDAQ:AVRO) (the "Company"), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the Company has granted a non-statutory stock

  25. AVROBIO Announces First Patient Dosed Using plato™ Platform

    Patient is the fourth dosed in Phase 2 trial of AVR-RD-01, an investigational gene therapy for Fabry disease plato is AVROBIO's platform for worldwide gene therapy commercialization AVROBIO (NASDAQ:AVRO) (the

  26. AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    AVROBIO (NASDAQ:AVRO) (the "Company"), a leading clinical stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the Company has granted a non-statutory stock

  27. AVROBIO, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

    Dosing of first Fabry patient incorporating plato™ anticipated for fourth quarter 2019 All Fabry patients who discontinued enzyme replacement therapy (ERT) following treatment with AVR-RD-01 investigational gene

  28. AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR‑RD‑02 for the Treatment of Gaucher Disease

    AVROBIO, Inc. (NASDAQ:AVRO) (the "Company"), today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for the Company's investigational gene therapy, AVR-RD-02, for the

  29. AVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis

    Investigational Therapy Designed to Engineer Patients' Own Stem Cells to Produce Essential Protein AVROBIO, Inc. (NASDAQ:AVRO) (the "Company") today announced that the first patient has been dosed in the Company's

  30. AVROBIO, Inc. to Present at Chardan's 3rd Annual Genetic Medicines Conference

    AVROBIO, Inc. (NASDAQ:AVRO), a Phase 2 clinical-stage gene therapy company, today announced that Geoff MacKay, President and CEO of AVROBIO, will present at Chardan's 3rd Annual Genetic Medicines Conference on Monday,

  31. AVROBIO, Inc. to Present at Upcoming Investor Conferences

    AVROBIO, Inc. (NASDAQ:AVRO) a Phase 2 clinical-stage gene therapy company, today announced that members of its senior management team are scheduled to participate in five upcoming investor conferences. Citi's 14th